SkinBioTherapeutics (LSE:SBTX) has had a turbulent year, including a trading suspension, an investigation into its former chief executive and a restatement of its prior-year accounts. Its trading statement of 22 September 2026 turns attention back to the Business itself, reporting higher Revenue for the year to 30 June 2026 but a much lower cash balance. This article looks at where that growth came from and what the falling cash figure means.

The business

SkinBioTherapeutics is an AIM-quoted life science company focused on skin health and the microbiome. It operates a products division, which includes Dermatonics topical skincare for barrier repair and foot health, and AxisBiotix, an oral supplement aimed at inflammatory skin conditions that has been stocked in around 180 Superdrug stores. Its microbiome-based ingredient Zenakine is licensed to Croda. The services side is Bio-Tech Solutions (BTS), a contract Manufacturing and packaging business for the health and personal care sectors, which the group acquired during its 2025 financial year.

The September trading statement

On 22 September 2026, the company said it expected revenue of about £4.7 million for the year to 30 June 2026, compared with restated revenue of £3.9 million in the previous year, an increase of roughly 20.5%. BTS contributed £2.1 million, up from £1.4 million over nine months of ownership in the prior year, and the company put BTS's underlying growth, excluding intercompany sales, at about 10%. Interim chair Alyson Levett said revenue growth principally reflected "the full-year contribution from BTS".

The adjusted EBITDA loss was expected to be £1.6 million, against a restated £1.7 million. The company also reported one-off costs of £1.2 million, comprising about £0.7 million of direct investigation costs and £0.5 million of other legal and employment costs. Cash at 30 June 2026 was £1.5 million, down from £4.8 million a year earlier. The board said it had sufficient cash reserves to support current operations and planned activities, and that trading in the early months of the new financial year had been ahead of management's internal expectations. Audited results are expected later in the year, subject to the auditor's review. The board listed its priorities as revenue growth, reducing the underlying operating loss and preserving cash.

Background to the restatement

Results for the half-year to 31 December 2025, published on 8 June 2026, included a restatement of the 2025 accounts. Revenue for that year was reduced from £4.64 million to £3.87 million after the removal of £0.77 million of accrued Royalty revenue. The company said documentation supporting that revenue was identified by FRP Advisory as fabricated by the former chief executive, and that no evidence had been found of anyone else's involvement. Trading in the shares, suspended on 1 April 2026, was restored on 8 June 2026. An interim chief financial officer was appointed in August.

Risks and what to watch

The largest risk is cash. A fall of more than £3 million in a year, including the investigation costs, leaves limited headroom if losses persist, and the trading statement figures are unaudited and could still change before publication. Growth has relied heavily on the acquired BTS business, while product sales remain modest. The company has said it intends to pursue recovery of investigation costs through legal proceedings, but the outcome is uncertain. The audited FY26 results, and confirmation of the auditor's view on going concern, will be important markers, as will any board appointments that settle the interim Leadership arrangements.

Conclusion

SkinBioTherapeutics grew revenue in FY26 mainly because of a full year of contract manufacturing from BTS, while its adjusted operating loss narrowed slightly. However, one-off costs and continuing losses cut cash sharply, so the company's position depends on sustaining the improved trading it has reported and controlling spending.